AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

AdAlta Limited (ASX:1AD) is pleased to announce the publication of the pre-clinical studies supporting the clinical development of its first in class antifibrotic agent, AD-214, in the peer reviewed journal mAbs. AD-214 is being developed as a novel approach to treating fibrotic diseases such as the degenerative and fatal Idiopathic Pulmonary Fibrosis (“IPF”) and kidney fibrosis and has completed two Phase I clinical trials.

Founding Chief Scientist, Professor Mick Foley, commented: “Taken together, these data provide proof of concept for AD-214 as a novel treatment strategy for IPF and suggest that clinically feasible dosing regimens may be efficacious. This publication marks the first time the pre-clinical research that supported the clinical development of AD-214 for IPF has been brought together and peer reviewed. This makes our research significantly more accessible to potential partners and collaborators.”

The paper may be accessed here: https://doi.org/10.1080/19420862.2025.2505090 

New AD-214 publication

Summary